1 / 21

Scaling up ART in Sénégal: specifics needs for strategic information

This article discusses the specific needs and challenges faced in scaling up antiretroviral therapy (ART) in Senegal. It explores the importance of strategic information and monitoring and evaluation systems in achieving nationwide access to ART. The article also highlights the need to strengthen human resources and systematic data collection for effective implementation.

Download Presentation

Scaling up ART in Sénégal: specifics needs for strategic information

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Scaling up ART in Sénégal: specifics needs for strategic information Mame Awa Toure MD, MSc AIDS/STI Division, MOH Senegal

  2. Introduction • Senegal: a west African country • Area: 196.722 km² • Population estimated to 10 millions • 11 regions and 30 departments/ provinces. • Resources constrained settings: GDP of 500$ US. • Concentrated HIV epidemic • Low HIV prevalence in general population less than 2% • 5-20% in high risk group

  3. The Senegalese Initiative for Access to ARVs : ISAARV • A Governmental initiativelate 1997 • Political commitment : increasing annual subsidy • Collaboration of ANRS: technical support, project design • First step : Pilot study • Building up a model according limited resources • Evaluation before extension (collaboration with ANRS) • Second step : scale up for nationwide access

  4. 2000- 2006Accelerating phase of ISAARV • Political comittement • Government subsidy increased • Subsidy included to the national budget line • Credit IDA : MAP • Expanding Fund and Partnership for ARV program • government, • WB, GF, USAID/FHI, UE, GTZ, UN agencies… • Decrease of the of financialparticipation • Increasing demand

  5. Increasing government budget

  6. Financial participation • Government subsidycon’t • October 2000: ACCESS Program • Levels of financial participation • SES assessed by a social workers team • A package including drugs, CD4 count and viral load • Low income: $30- $7 per month • Government officers $60- $15 • About 80% of patients treated free of charge

  7. ISAARV managerial structures • Health facilities level: hospital/treatment centers • Medical committees • Enrollment and medical follow up • PEP documentation and management • Psycho-social support committees • Adherence support, accompaniment counseling… • PLWHA clubs • Coordination level: HIV/AIDS Division, MOH • Drugs and reagents management committee • PMTCT management committee • VCT piloting committee

  8. Services delivery package • District level : operational level • Counseling, certain OI management, • * PMTCTservices, • Referral functional system, • Monitoring ARV (next step) • Hospital level : district + ARV • ARV entry point • Rapid functionality of structures

  9. Needs, coverage • ISAARV components • prior Conditions: • HIV testing available/ VCT • ARV Treatment Centers • Counseling, treatment of OI, use of Cotrimo… • Laboratories capacity : CD4, routine exams • Training of health personals • ARV monitoring committees

  10. Needs, coverage (2) • Monitoring ART • Adults,Children, • PMTCT • Post Exposure Prophylaxis • Psycho-social and adherence support • Supportive research: • Monitoring drugs resistance • Promoting clinical trials

  11. Chain of distribution • National procurement pharmacy • Treatment centersRegional procurementpharmacy Fann Pharmacy Regional hospital/ Districts HPD, IHS

  12. ISAARV up to date • 1350 patients included Period Aout 98 - may 2003 • 5 out of 11 regions involved • Active local sponsorship in process • Extension to the remaining regions by end of 2003

  13. How does the data collection work? • Patient monitoring • Detailed patient data base for the first 100 naives patients enrolled to the pilot phase, • Database on 80 patients enrolled in the two clinical trials ANRS1204/ ANRS1206 • Few initiatives on the remaining • Data not being collected regularly • Lack of systematized data collection

  14. Strategic objectives • Nationwide access to ARV drugs planned • Strenghten capacities in the 11 regions • Increasing number of PLWHA treated • 7000 patients by 2006 •  M&E system urgently needed!!! • Weak part of the program to be improved

  15. M&E approach • M&E system already in place • For other priority diseases • except HIV/AIDS new strategies (PMTCT, ART..) • Building up process for HIV/AIDS: • Capacity building** • M&E Unit: NACA, MOH, and other ministries • Strengthening technical resources: training

  16. M&E approach (2) • M&E plan developed • Workshop in June 2003: set of indicators for each components ** (UNGASS/MAP) • M&E tools and Operational guidelines to be developed • training • Data collection plan

  17. M&E approach (5)

  18. M&E approach(4)next steps by end of 2003 • Workshop series • Update and reinforce competencies in M&E within targeted sectors (health, education, youth…) • Priority for the Health sector • TOT, training series • M&E tools development • Data collection plan • Data collection forms • Defining evaluation system and calendar • M&E sub- units to be set up at the regional level, • Contracting services ???

  19. Specifics needs • Lack of technical resources : • Urgent need to • Strenghten HR capacities in M&E • Recruit human resources for M&E units at each level • More use of available data • Systematisation of information, • Regular data collection • For patient monitoring and program monitoring

  20. Specifics needs • ARV delivery system to be improved • Logistical issues • Better planning of Evaluations for all ISAARV components • Evaluation of the pilot phase (ANRS 02) • More in-dept Cost-effectiveness analysis • External expertise needed

More Related